ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89 Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol.
Fiona Hegi-JohnsonStacey E RuddChristian WichmannTim AkhurstPeter RoseltJenny TrinhThomas JohnLisa DevereuxPaul S DonnellyRod HicksAndrew M ScottDaniel SteinfortStephen FoxBenjamin BlythSagun ParakhGerard G HannaJason CallahanKate BurburyMichael MacManusPublished in: BMJ open (2022)
Australian Clinical Trials Network ACTRN12621000171819.
Keyphrases
- positron emission tomography
- pet ct
- clinical trial
- pet imaging
- open label
- study protocol
- double blind
- small cell lung cancer
- computed tomography
- randomized controlled trial
- high resolution
- rectal cancer
- phase ii
- placebo controlled
- locally advanced
- phase iii
- advanced non small cell lung cancer
- radiation therapy
- fluorescence imaging
- brain metastases